{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:29:32Z","timestamp":1786508972802,"version":"build-2736575974"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.jvca.2026.07.030","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:58:55Z","timestamp":1784534335000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Cardiovascular Pharmacotherapy. X. Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure and Mechanisms of Protection"],"prefix":"10.1053","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2026.07.030_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCHEARTFAILURE.108.766402","article-title":"Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat","volume":"1","author":"Poornima","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0002","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","article-title":"Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy","volume":"110","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.030_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCHEARTFAILURE.109.900282","article-title":"Glucagon-like peptide-1 increases myocardial glucose intake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy","volume":"3","author":"Bhashyam","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0004","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0005","first-page":"140","article-title":"The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation via indirect mechanisms and mitigates experimental diabetic cardiomyopathy","volume":"37","author":"Almutairi","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0006","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/db15-1224","article-title":"Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice","volume":"65","author":"Mulvihill","year":"2016","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0007","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.030_bib0008","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.2337\/db16-1206","article-title":"Glucagon-like peptide-1 receptor activation augments cardiac output and improves cardiac activity in obese swine after myocardial infarction","volume":"66","author":"Sassoon","year":"2017","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0009","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac structure and function in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0011","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-011-2440-x","article-title":"Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety","volume":"55","author":"Nathanson","year":"2012","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2026.07.030_bib0012","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0013","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: Cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0014","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0735-1097(97)00185-X","article-title":"Insulin resistance in chronic heart failure: Relation to severity and etiology of heart failure","volume":"30","author":"Swan","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardiores.2003.11.027","article-title":"The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy","volume":"61","author":"Nikolaidis","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1568008054064869","article-title":"Myocardial insulin resistance and cardiac complications of diabetes","volume":"5","author":"Abel","year":"2005","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1053\/j.jvca.2026.07.030_bib0017","doi-asserted-by":"crossref","first-page":"H1096","DOI":"10.1152\/ajpheart.00930.2009","article-title":"Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure","volume":"298","author":"Halbirk","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0018","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2016.01.008","article-title":"Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction","volume":"4","author":"Lepore","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0019","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","article-title":"Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure","volume":"57","author":"Arturi","year":"2017","journal-title":"Endocrine"},{"key":"10.1053\/j.jvca.2026.07.030_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cardfail.2014.10.012","article-title":"Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes","volume":"21","author":"Velez","year":"2015","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0021","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.07.030_bib0022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12020-015-0798-0","article-title":"Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction","volume":"52","author":"Chen","year":"2016","journal-title":"Endocrine"},{"key":"10.1053\/j.jvca.2026.07.030_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: Randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: A secondary analysis of the SOUL randomized clinical trial","volume":"186","author":"Pop-Busui","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0025","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0026","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0027","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","article-title":"Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice","volume":"32","author":"Kruger","year":"2026","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: A meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0029","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: A systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.030_bib0030","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.07.030_bib0031","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ehf2.12334","article-title":"Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: Insights from the FIGHT trial","volume":"5","author":"Sharma","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006758","article-title":"Effects of liraglutide on worsening renal function among patients with heart failure with reduced ejection fraction: Insights from the FIGHT trial","volume":"13","author":"Redouane","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0033","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1002\/ehf2.13348","article-title":"Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure","volume":"8","author":"Sharma","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0034","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1038\/s41598-022-12973-0","article-title":"Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with or without type 2 diabetes","volume":"12","author":"Lerman","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2026.07.030_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0036","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-020-01088-3","article-title":"Liraglutide in the treatment of heart failure: Insight from FIGHT and LIVE","volume":"19","author":"Liang","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0037","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/1573399816999200821164129","article-title":"Systematic review of glucagon-like peptide one receptor agonist liraglutide of subjects with heart failure with reduced left ventricular ejection fraction","volume":"17","author":"Hamad","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"10.1053\/j.jvca.2026.07.030_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004885","article-title":"A protocol for a randomised, double-blind, placebo-controlled study of the effects of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes (the LIVE study)","volume":"4","author":"Jorsal","year":"2014","journal-title":"BMJ Open"},{"key":"10.1053\/j.jvca.2026.07.030_bib0039","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with or without diabetes (LIVE)\u2014A multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12350-017-1000-2","article-title":"Effect of liraglutide on myocardial oxygen uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study","volume":"26","author":"Nielsen","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0041","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/14017431.2020.1751873","article-title":"Heart rate increases in liraglutide treated chronic heart failure patients: Association with clinical parameters and adverse events","volume":"54","author":"Tougaard","year":"2020","journal-title":"Scand Cardiovasc J"},{"key":"10.1053\/j.jvca.2026.07.030_bib0042","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/dom.14135","article-title":"The impact of glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes","volume":"22","author":"Nielsen","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0043","doi-asserted-by":"crossref","first-page":"xvag111","DOI":"10.1093\/eschf\/xvag111","article-title":"Glucagon-like peptide receptor agonists in patients with heart failure with reduced ejection fraction","volume":"13","author":"Kassab","year":"2026","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0044","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lower drugs in patients with heart failure","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0045","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jchf.2018.06.002","article-title":"Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction","volume":"6","author":"Haykowsky","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0046","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.030_bib0047","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","article-title":"Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"6","author":"Rao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0048","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jchf.2018.08.007","article-title":"Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF","volume":"6","author":"Kitzman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0049","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: New insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0050","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction. JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0051","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.1788","article-title":"Quality of left in heart failure with preserved ejection fraction: Importance of obesity, functional capacity, and physical inactivity","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0052","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0053","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0054","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0055","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0056","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cmet.2023.08.003","article-title":"A big STEP for treatment of heart failure with preserved ejection fraction","volume":"35","author":"Verma","year":"2023","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0057","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: A prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0058","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0059","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: A prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.030_bib0060","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.030_bib0061","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/ejhf.70049","article-title":"Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme","volume":"27","author":"Pandey","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0062","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","article-title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): A prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","volume":"13","author":"Davies","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102660","article-title":"Semaglutide and exercise function in obesity-related HFpEF: Insights from the STEP-HFpEF program","volume":"13","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0064","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.030_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: Insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0066","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0067","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: The STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102610","article-title":"Frailty and effects of semaglutide in obesity-related HFpEF: Findings from the STEP-HFpEF program","volume":"13","author":"Pandey","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2026.07.030_bib0069","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: The STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0070","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0071","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0072","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.030_bib0073","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0074","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0075","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: The SUMMIT trial","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0076","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.030_bib0077","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV Mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0078","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: The SUMMIT trial","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0079","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: A prespecified stratification-based analysis","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0080","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","volume":"334","author":"Kruger","year":"2025","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.07.030_bib0081","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated by both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.07.030_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like peptide-1 receptor Tie2+ cells are essential for cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0083","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.yjmcc.2015.09.018","article-title":"Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium","volume":"89","author":"Wallner","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0084","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"10.1053\/j.jvca.2026.07.030_bib0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0086","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-13-36","article-title":"Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptide levels in obese type 2 diabetes patients","volume":"13","author":"Li","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0087","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130894","article-title":"Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart","volume":"10","author":"Aravindhan","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.07.030_bib0089","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023570","article-title":"Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia\/reperfusion injury: Evidence for improving cardiac metabolic efficiency","volume":"6","author":"Bao","year":"2011","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.07.030_bib0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-014-0132-9","article-title":"Exendin-4 ameliorates cardiac ischemia\/reperfusion injury via caveolae and caveolins-3","volume":"13","author":"Tsutsumi","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0091","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0092","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0093","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.030_bib0094","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","article-title":"Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia","volume":"5","author":"Lonborg","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2026.07.030_bib0095","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0096","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/db13-1849","article-title":"Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: Results from a randomized study","volume":"63","author":"Lonborg","year":"2014","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0097","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12933-018-0784-y","article-title":"Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: Sub study of the phase II\/III ExSTRESS randomized trial","volume":"17","author":"Besch","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0098","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijcard.2016.06.283","article-title":"No benefit of additional treatment with exenatide in patients with an acute myocardial infarction","volume":"220","author":"Roos","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0099","first-page":"1285","article-title":"Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression","volume":"19","author":"Hamaguchi","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1053\/j.jvca.2026.07.030_bib0100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010321","article-title":"GLP-1 is a coronary artery vasodilator in humans","volume":"7","author":"Clarke","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.07.030_bib0101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijcard.2018.12.005","article-title":"Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction","volume":"283","author":"Suhrs","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0102","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","article-title":"Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials","volume":"28","author":"Fonseca","year":"2014","journal-title":"J Diabetes Complications"},{"key":"10.1053\/j.jvca.2026.07.030_bib0103","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0104","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0105","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0106","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0107","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.030_bib0108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.030_bib0109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0110","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0111","article-title":"Glucagon-like peptide-1 receptor agonists and the endothelium: Molecular and clinical insights into cardiovascular protection","volume":"12","author":"Battistoni","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.jvca.2026.07.030_bib0112","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2936667","article-title":"Liraglutide improves endothelial function via mTOR signaling pathway","volume":"2021","author":"Wu","year":"2021","journal-title":"J Diabetes Res"},{"issue":"Suppl","key":"10.1053\/j.jvca.2026.07.030_bib0113","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1194\/jlr.R800069-JLR200","article-title":"Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer\u2019s disease to AIDS","volume":"50","author":"Mahley","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0114","first-page":"3350","article-title":"Exendin-4 reverses endothelial dysfunction in mice fed a high-cholesterol diet by a GTP cyclohydrolase-1\/tetrahydrobiopterin pathway","volume":"18","author":"Tang","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1053\/j.jvca.2026.07.030_bib0115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/db11-1073","article-title":"Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism","volume":"61","author":"Chai","year":"2012","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0116","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sjoberg","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0117","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protect by liraglutide in mice with experimental hypertension","volume":"40","author":"Helmstader","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0118","doi-asserted-by":"crossref","first-page":"E1289","DOI":"10.1152\/ajpendo.00373.2007","article-title":"Beneficial effects of GLP-1 on endothelial function in humans: Dampening by glyburide but not by glimepiride","volume":"293","author":"Basu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0119","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/hsz-2019-0386","article-title":"The cGMP system: Components and function","volume":"401","author":"Hofmann","year":"2020","journal-title":"Biol Chem"},{"key":"10.1053\/j.jvca.2026.07.030_bib0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1479164112449562","article-title":"Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research","volume":"10","author":"Irace","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0121","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-025-02607-w","article-title":"The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: A potential avenue for improving heart failure with preserved ejection fraction (HFpEF)","volume":"24","author":"Hullon","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0122","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","article-title":"Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor","volume":"325","author":"Erdogdu","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0123","doi-asserted-by":"crossref","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109537","article-title":"Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice","volume":"120","author":"Han","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.jvca.2026.07.030_bib0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/1479164114547358","article-title":"The effect of liraglutide on endothelial function in patients with type 2 diabetes","volume":"11","author":"Nandy","year":"2014","journal-title":"Diab Vasc Dis Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0126","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1475-2840-11-64","article-title":"Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: A randomized trial","volume":"11","author":"Kelly","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0127","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.201148","article-title":"Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor","volume":"11","author":"Medak","year":"2026","journal-title":"JCI Insight"},{"key":"10.1053\/j.jvca.2026.07.030_bib0128","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.medj.2021.10.004","article-title":"Cardiorenal mechanism of action of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"2","author":"Cherney","year":"2021","journal-title":"Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41598-020-80894-x","article-title":"Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: The earlier, the better","volume":"11","author":"Sanada","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2026.07.030_bib0131","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2026.07.030_bib0132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168396","article-title":"Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-\/- mice","volume":"11","author":"Bisgaard","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.07.030_bib0133","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.119.258343","article-title":"Liraglutide attenuates preestablished atherosclerosis in apolipoprotein E-deficient mice via regulation of immune cell phenotypes and proinflammatory mediators","volume":"370","author":"Bruen","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.jvca.2026.07.030_bib0134","article-title":"Cathepsin S: Molecular mechanisms in inflammatory and immunological processes","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0135","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2022.05.055","article-title":"Cathepsin S levels and survival among patients with non-ST-segment elevation acute coronary syndrome","volume":"80","author":"Stamatelopoulos","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0136","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1093\/eurheartj\/ehag060","article-title":"Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity","volume":"47","author":"Kassab","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.030_bib0137","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","article-title":"Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study","volume":"15","author":"Rizzo","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0138","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2337\/dc20-2014","article-title":"The effect of exenatide once weekly on carotid atherosclerosis in individuals with type 2 diabetes: An 18-month randomized placebo-controlled study","volume":"44","author":"Koska","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1053\/j.jvca.2026.07.030_bib0139","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.jacc.2019.01.077","article-title":"Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention","volume":"73","author":"Guedeney","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2026.07.030_bib0141","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2026.07.030_bib0142","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41419-023-06206-z","article-title":"Macrophage polarization and metabolism in atherosclerosis","volume":"14","author":"Hou","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1053\/j.jvca.2026.07.030_bib0143","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2026.07.030_bib0144","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinue","year":"2017","journal-title":"Diabetologia"},{"key":"10.1053\/j.jvca.2026.07.030_bib0145","article-title":"Glucagon-like peptide-1 receptor agonists: New strategies and therapeutic targets to treat atherosclerotic cardiovascular disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0146","first-page":"288","article-title":"Gastrointestinal incretins-glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) beyond pleiotropic physiological effects are involved in pathophysiology of atherosclerosis and coronary artery disease\u2014State of the art","volume":"11","author":"Jonik","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1053\/j.jvca.2026.07.030_bib0147","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.athplu.2022.05.004","article-title":"Semaglutide treatment attenuates vessel remodeling in ApoE-\/- mice following vessel injury and blood flow perturbation","volume":"49","author":"Jensen","year":"2022","journal-title":"Atheroscler Plus"},{"key":"10.1053\/j.jvca.2026.07.030_bib0148","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tcm.2019.01.004","article-title":"Inflammation, infection and atherosclerosis","volume":"29","author":"Shah","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0149","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"10.1053\/j.jvca.2026.07.030_bib0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0151","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation","volume":"269","author":"Martinez","year":"2018","journal-title":"Arteriosclerosis"},{"key":"10.1053\/j.jvca.2026.07.030_bib0152","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.07.030_bib0153","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.jvca.2026.07.030_bib0154","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analysis of three randomized, double-blind, placebo-controlled phase 3 trials","volume":"55","author":"Verma","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1053\/j.jvca.2026.07.030_bib0155","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/eurheartj\/ehaf690","article-title":"Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: The SEMA-VR CardioLink-15 trial","volume":"47","author":"Park","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.07.030_bib0156","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.3390\/jcm14196758","article-title":"GLP-1 agonists in cardiovascular diseases: Mechanisms, clinical evidence, and emerging therapies","volume":"14","author":"Yang","year":"2025","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2026.07.030_bib0157","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0158","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/hsz-2012-0119","article-title":"Mitophagy: Mechanisms, pathophysiological roles, and analysis","volume":"393","author":"Ding","year":"2012","journal-title":"Biol Chem"},{"key":"10.1053\/j.jvca.2026.07.030_bib0159","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/molecules28031369","article-title":"Cardiovascular protection with a long-acting GLP-1 receptor agonist liraglutide: An experimental update","volume":"28","author":"Vandemark","year":"2023","journal-title":"Molecules"},{"key":"10.1053\/j.jvca.2026.07.030_bib0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0161","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109252","article-title":"GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1b-induced metabolic disturbance and mitochondrial dysfunction","volume":"332","author":"Zhang","year":"2020","journal-title":"Chem Biol Interact"},{"key":"10.1053\/j.jvca.2026.07.030_bib0162","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157339907780598225","article-title":"Diabetic vasculopathy and the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)","volume":"3","author":"Renie","year":"2007","journal-title":"Curr Diabetes Rev"},{"key":"10.1053\/j.jvca.2026.07.030_bib0163","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.diabres.2018.05.019","article-title":"Malondialdehyde-modified LDL-related variables are associated with diabetic kidney disease in type 2 diabetes","volume":"141","author":"Furukawa","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.jvca.2026.07.030_bib0164","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1053\/j.jvca.2026.07.030_bib0165","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1053\/j.jvca.2025.05.010","article-title":"Advances in cardiovascular pharmacotherapy. III. Sodium-glucose cotransporter type 2 inhibitors, part 1: Efficacy in heart failure and myocardial infarction","volume":"39","author":"Pagel","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.07.030_bib0166","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026006154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026006154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:56:09Z","timestamp":1786506969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077026006154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":166,"alternative-id":["S1053077026006154"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2026.07.030","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. X. Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure and Mechanisms of Protection","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2026.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}